Get started
Guard Therapeutics International ABGuard Therapeutics International ABGuard Therapeutics International AB

Guard Therapeutics International AB

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonals

Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Earnings, Q1 FY2026
May 11, 2026
Q1 loss narrowed, cash reserves rose, and delisting looms pending strategic alternatives.
2025
Earnings, Q4 FY2025
Annual
Feb 20, 2026
Clinical program ended after failed phase 2b; strategic review underway with cash for 2026.
Earnings, Q3 FY2025
Nov 13, 2025
Negative POINTER study results prompt strategic review and development pause.
Study Result
Oct 27, 2025
POINTER phase 2B failed to show RMC-035 benefit, prompting strategic review and likely discontinuation.
DNB Carnegie Småbolagsdag
Sep 1, 2025
Phase 2B kidney trial nears results, with strong data and major partnering discussions ongoing.
Earnings, Q2 FY2025
Aug 21, 2025
Phase 2b POINTER study recruitment completed early; positive safety review and SEK 120M raised.
Earnings, Q1 FY2025
May 5, 2025
Q1 saw rapid clinical progress and SEK 120m in new funding, despite a widened loss.
2024
Earnings, Q4 FY2024
Annual
Feb 20, 2025
RMC-035 advanced in clinical trials with robust funding and promising kidney protection data.
Earnings, Q3 FY2024
Nov 13, 2024
Phase 2b POINTER study underway; RMC-035 targets $1B+ global market in cardiac surgery.
Earnings, Q2 FY2024
Aug 22, 2024
Regulatory progress and new funding position Guard Therapeutics for key clinical milestones.
Earnings, Q1 FY2024
May 8, 2024
R&D Update
Jan 30, 2024
2023
Earnings, Q4 FY2023
Annual
Feb 21, 2024
ABGSC Investor Days
Nov 22, 2023
Earnings, Q3 FY2023
Nov 10, 2023
Study Result
Sep 19, 2023
Earnings, Q2 FY2023
Aug 24, 2023
Earnings, Q1 FY2023
May 9, 2023